Compare Church & Dwight Co., Inc. (CHD) vs Cronos Group Inc (CRON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Church & Dwight Co., Inc. vs Cronos Group Inc — how do they compare? Church & Dwight Co., Inc. trades at $102.84 (market cap $24.50B), while Cronos Group Inc trades at $3.08 (market cap $1.11B). The key difference: Church & Dwight Co., Inc. is far larger — about 22.1× Cronos Group Inc's market cap, and Church & Dwight Co., Inc. pays a 1.19% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CHD | CRON | |
|---|---|---|
Market Cap | $24.50B | $1.11B |
Sector | Consumer Staples | Health |
52-Week High | $105.26 | $3.27 |
52-Week Low | $81.60 | $2.30 |
Enterprise Value | $26.50B | $310.67M |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Church & Dwight (CHD) trades at $103.24, slightly below the consensus price target of $103.57, with a modest 24-hour decline of 0.12%. The stock exhibits a bullish technical trend, supported by moving averages, while fundamentals show steady revenue growth to $6.20 billion in 2025 and a net income margin of 11.96%. Recent Q2 2026 earnings matched estimates with organic sales growth of 5.8%, prompting raised full-year guidance. Analyst sentiment is positive with 53% buy ratings, though valuation multiples like a P/E of 33.09 suggest premium pricing.
The outlook remains favorable due to strong brand performance and raised earnings guidance, but risks include elevated debt levels and competitive pressures in consumer staples. Institutional activity shows mixed positions, with some funds reducing stakes. The stock's upside is capped by high valuations, requiring sustained earnings growth to justify current levels.
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →
